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Sutter1,2, Elien Vandermarliere1,2, Evy Timmerman1,2, Kris Gevaert1,2, Lennart Martens1,2 & 
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The use of protein tagging to facilitate detailed characterization of target proteins has not only 
revolutionized cell biology, but also enabled biochemical analysis through efficient recovery of the 
protein complexes wherein the tagged proteins reside. The endogenous use of these tags for detailed 
protein characterization is widespread in lower organisms that allow for efficient homologous 
recombination. With the recent advances in genome engineering, tagging of endogenous proteins 
is now within reach for most experimental systems, including mammalian cell lines cultures. In 
this work, we describe the selection of peptides with ideal mass spectrometry characteristics for 
use in quantification of tagged proteins using targeted proteomics. We mined the proteome of the 
hyperthermophile Pyrococcus furiosus to obtain two peptides that are unique in the proteomes of 
all known model organisms (proteotypic) and allow sensitive quantification of target proteins in a 
complex background. By combining these ’Proteotypic peptides for Quantification by SRM’ (PQS 
peptides) with epitope tags, we demonstrate their use in co-immunoprecipitation experiments upon 
transfection of protein pairs, or after introduction of these tags in the endogenous proteins through 
genome engineering. Endogenous protein tagging for absolute quantification provides a powerful extra 
dimension to protein analysis, allowing the detailed characterization of endogenous proteins.
Epitope tags are widely used in cell biology and biochemical analysis1. They enable the detection of the protein 
in the cell and allow the purification of the associated protein complex. Many epitope tags exist, ranging from 
short peptide sequences (e.g., FLAG™ 2 and CaptureSelect™ 3) to intact proteins (e.g., Green Fluorescent Protein4, 
mutant BirA5 and Halo tag6). However, none of these tags allow for a direct quantification of the protein. Protein 
levels can be obtained by antibody-based approaches such as classical enzyme-linked immunosorbent assays 
(ELISA) experiments with theoretical detection and quantification limits in the zeptomolar concentration range7. 
In practice however, detection limits are often hampered by inadequate or non-specific antibodies, blocking of 
epitope sites by post-translational modifications (PTMs) or epitope masking by protein folding or interactors8. An 
alternative quantification strategy relies on the use of targeted mass spectrometry (MS) to monitor the expression 
level of a protein. Selective ion monitoring (SIM), selective reaction monitoring (SRM) and, more recently, paral-
lel reaction monitoring (PRM) are targeted proteomics strategies that were developed to analyze specific proteins 
or protein modifications and are therefore increasingly used in translational research9. All of this resulted in the 
selection of SRM as the method of the year 2012 by the journal Nature Methods10. In these approaches, specific 
peptides are selected as representative reporter peptides for the protein of interest and allow either direct quanti-
fication, or indirectly by spiking a reference peptide that contains stable isotopic labels.
SRM experiments are typically performed on triple quadrupole instruments where the first (Q1) and the last 
(Q3) quadrupoles are used in a static manner to filter specific predefined precursor and fragment ions respec-
tively, while in the second quadrupole (Q2) collision-induced dissociation of the precursor ion takes place11. In 
contrast to discovery MS, SRM does not rely on the acquisition of full-range m/z spectra but rather records the 
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intensity over time for preselected m/z values. The combination of these predefined m/z values of the precursor 
and fragment ions are commonly denoted as transitions11.
In targeted proteomics, samples are first processed by the use of a robust protocol, followed by complete prote-
olytic digestion with trypsin or other proteases. Depending on sample complexity and target concentration, sepa-
ration schemes can vary, with complex orthogonal fractionation strategies for sensitive detection of low abundant 
proteins12,13. Specific antibody-based peptide enrichment approaches such as Stable Isotope Standard Capture 
with Anti-Peptide Antibodies (SISCAPA)14, immunoaffinity depletion of abundant proteins or chromatographic 
optimizations are also used15,16.
Despite the clear use for targeted proteomics, especially as a verification step in biomarker studies to reduce 
the number of candidates coming from discovery screens17, assay development remains challenging, which 
recently culminated in an effort to standardize assay design and reporting18. As PTMs may interfere with the 
readout of specific SRM peptides, multiple peptides of a protein need to be monitored for a reliable protein 
assay. In addition, the selected peptides need to be proteotypic for the sample (i.e. unique for the protein given 
the background proteome in which the protein of interest is monitored), while sample complexity can impede 
signal-to-noise ratios (S/N) and liquid chromatography retention times9.
By using cleavable reporter peptides, equimolar amounts of a protein reference peptide and a universal pep-
tide can be introduced in the sample, facilitating precise analysis19. Next to inaccurate stable isotope labeled 
reference peptide quantification20, incomplete digestion can also hamper robust quantification. In an attempt 
to correct for possible variation in digestion efficiency, labeled peptides are often synthesized with flanking 
sequences that mimic the actual protein sequence and thus approximate the endogenous tryptic context. This 
led to the emergence of advanced strategies over the last years, with QconCAT as the best-known example21,22. 
Peptides can be generated by classical synthesis or by expression of several concatenated peptides from a custom 
expression vector in cells cultured in media containing selected heavy labeled amino acids.
Co-immunoprecipitation (Co-IP) is a classical approach to show an interaction between two proteins. 
Transient expression of both tagged bait and prey proteins is typically used for these experiments, although the 
application of specific primary antibodies for both proteins is becoming increasingly popular and often required 
to ascertain an interaction on the endogenous level. In Co-IP, protein complexes are typically eluted from the 
purification beads and analyzed directly by Western blot which results in a semi-quantitative read-out.
In this report, we describe the selection of Proteotypic peptides for Quantification by SRM (PQS peptides) 
from the unique proteome of the hyperthermophile Pyrococcus furiosus. After several rounds of selection, two 
peptides were retained and evaluated for direct sensitive detection and quantification in complex lysates. These 
PQS peptides were also introduced as peptide tags in different target proteins, providing a universal quantita-
tive read-out system for the tagged proteins. In addition, we performed binary protein-protein interaction (PPI) 
assays for different pairs of tagged proteins expressed from vectors in human cells, and for a binary interaction 
between two endogenous proteins after introduction of the PQS peptide sequences in the genome sequence of 
the target proteins.
Results
Initial selection of peptides based on P. furiosus proteome analysis. To enable sensitive SRM-based 
quantification using a protein tagging strategy, we first needed to define optimal peptides that could be developed 
into a universal SRM assay. We rationalized that such peptides should adhere to the following criteria. 1) The 
peptides need to show good LC-MS(/MS) properties, including ionization and fragmentation, to maximize assay 
sensitivity. Ideally, such peptides can be detected in complex samples such as digested whole cell lysates without 
the need for fractionation prior to detection. 2) The SRM peptides are unique or proteotypic for a wide range of 
commonly used model organisms in life sciences research. 3) The peptides allow for quantification in complex 
samples. 4) The peptides should be generated very efficiently by trypsin, minimizing potential quantification 
deviations when performing Stable Isotope Dilution (SID) experiments. 5) Finally, heavy labeled counterparts 
should be straightforward to produce and easy to handle (e.g. not prone to precipitation).
To maximize the chance of retrieving unique peptides with all of these properties, we reasoned that a pro-
teomic analysis of P. furiosus, a well-characterized hyperthermophile archaeon which thrives at an optimum 
growth temperature of 100 °C23, should lead to rapid identification of peptides with the desired specifications. 
The remarkable characteristics of P. furiosus are encoded in a genome that is drastically different from most other 
species which leads to an overlap of merely seven tryptic peptides upon comparison with human protein tryptic 
peptides24. Despite this discrepancy, Vaudel et al. showed that peptides from both proteomes show a very similar 
behavior in LC-MS systems24. Therefore, the Agilent complex proteomics standard (i.e. a lyophilized total soluble 
P. furiosus extract) was digested, fractionated and analyzed by LC-MS/MS. This standard is predicted to contain 
the majority of the approximately 2,000 known proteins that P. furiosus encodes for and led here to the identifi-
cation of 1,581 unique peptide sequences, originating from 582 unique proteins, that were retained for further 
selection and validation. An overview of the complete peptide triage workflow is provided in Fig. 1.
To narrow down the number of suitable peptides, the data obtained from the P. furiosus discovery experiments 
were further processed to create a shortlist of peptides that show optimal LC-MS characteristics. To this end, 
average matched intensities were calculated for each peptide that uniquely matched a single protein. Differential 
scores were subsequently calculated for all peptides based on the Huber median and mean absolute deviation 
(MAD) values as defined in experimental procedures. These differential scores were then averaged for each pep-
tide across the three discovery experiments. A second calculation was done for the fragmentation efficiency, 
represented by the fragment ion coverage. For each identified peptide, the number of annotated ions for every 
spectrum were summed and averaged over the three discovery experiments.
Following calculations, the peptides were filtered in an elimination process where peptides with at least one 
of the following criteria were discarded: 1) peptides that contain methionines or cysteines (oxidation effects), 2) 
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peptides that show missed cleavages, 3) peptides that start with glutamine (non-quantitative pyro-glutamic acid 
formation), 4) peptides that show consecutive prolines (elution peak broadening) and 5) peptides that are shorter 
than 9 amino acids. From the remaining list, a first set of peptides was selected by considering only peptides 
having a differential score >6 in all three replicates which resulted in a set of 7 peptides (indicated by selection 
method 1 in Table 1, Fig. 2A). A second selection of peptides was obtained by only considering peptides identified 
with at least 3 spectra for the differential score calculation. After elimination, only peptides with a differential 
Figure 1. Selection of universal proteotypic peptides for quantification by SRM. The P. furiosus UniProt 
database contained 2,139 proteins. By shotgun discovery proteome analysis on the Agilent complex proteomics 
standard, 1,581 unique candidate peptides were retrieved. Three in silico selection approaches reduced this 
number to 15. After experimental validation of the in silico predicted shortlist, two peptides were retained. PSM: 
peptide-spectrum match.
Rank in 
digest Peptide Abbreviation
Selection 
set
1 EAVSEILETSR EAV 2
2 GLGASPGIGAGR GLG 3
3 TIVVGSPNEK TIV 1
4 NTIEGAEITPQK NTI 1
5 VLGTPIEGIER VLG 1
6 ALELENVLDR ALE 1
7 AIETVDSAVR AIE 1
8 IESIEEAIK IES 2
9 GEIGEIPVVVEDR GEI 3
10 GGGPALIGIGESDSNNR GGG 3
11 AAAIVTDEGGR AAA 2
12 VGNPAETLVSK VGN 3
13 DLTSSIIQNENQHK DLT 3
14 EIATAGTLEGR EIA 1
15 GQDIAELEVR GQD 1
Table 1.  Overview of the 15 in silico predicted peptides and their corresponding ranking for intensity and 
equal distribution of transitions when spiked in a tryptic HCT116 digest. The last column depicts by which 
procedure the peptides were selected. The indicated abbreviation is the code the peptides were given during the 
experimental evaluation of the peptides.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:27220 | DOI: 10.1038/srep27220
score >2 and identified in the three replicates were retained, which in turn gave a set of 3 new peptides (indi-
cated by selection method 2 in Table 1, Fig. 2B). The last approach considered the average ion coverage as a 
selection criterion combined with identification in all three replicates. Only peptides showing an ion coverage of 
30 or higher were selected. This resulted in a selection of 5 peptides (indicated by selection method 3 in Table 1, 
Fig. 2C). Taken together, these 3 approaches led to a list of 15 potential peptides (Table 1). Next, we verified the 
uniqueness of the peptides irrespective of any cleavage rules by mapping the peptides back to protein databases. 
This analysis was done for all Eukaryota, and for all strains of E. coli. None of these peptide sequences were found 
in these protein databases, which include the vast majority of model organisms.
SRM-based evaluation of selected peptides. First, the selected peptides were optimized for LC-SRM by 
deriving the top 8 transitions with their best collision energy condition. The list of in silico predicted peptides was 
evaluated by spike in of a dilution series of this 15-peptide mix (Table 1) in a tryptic digest of a human colorectal 
carcinoma cell line lysate (HCT116, ATCC) followed by LC-SRM using optimized settings. Peptides that were 
readily detected in this complex matrix were further considered as the best candidates for use as universal PQS 
peptides. From this analysis, the two peptides that showed the highest intensity and the most equal distributed 
transitions were retained (Supplementary Figure S-1). These PQS peptides were further designated PQS1 (EAV) 
and PQS2 (GLG).
Sensitivity determination of PQS1 and PQS2 in a cellular background. To investigate the sensitiv-
ity associated with the highest ranked peptides EAVSEILETSR (PQS1) and GLGASPGIGAGR (PQS2), we spiked 
a dilution series of these peptides in a tryptic digest of HCT116 cells. Here, peptide levels varied over a dilution 
range from 6.4 fmol to 0.1 fmol detectable peptide in 0.5 μ g of HCT116 proteome digest (on column; quantities 
reported throughout this report refer to detectable peptide injected on the column, Fig. 3). Triplicate runs were 
averaged and plotted to determine the Limit of Detection (LOD) in a complex proteome background. For PQS1, a 
LOD of 100 amol was determined when an S/N higher than 3 was considered. Compensation for the non-linearity 
Figure 2. PQS Peptide selection strategy. Panel (A) shows the selection of a first set of peptides with consistent 
identification in the three replicates and with a differential score exceeding six (red dotted line). After filtering 
for suitable SRM peptides, this resulted in a set of seven peptides (labeled data points). Panel (B) shows a 
second selection of peptides where only peptides identified with at least three spectra were considered for the 
differential score calculation. After filtering for SRM application, only peptides with a differential score  
> two (red dotted line) and identified in all three replicates were retained, which in turn gave a set of three new 
peptides (labeled). The last approach panel (C) considered the average ion coverage as a selection criterion 
together with the consistent identification in all three replicates. Only peptides that show an ion coverage of 30 
or higher (red dotted line) were selected. From this analysis, five peptides (labeled) were added to the total list.
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of the calibration curve resulted in a LOD of 200 amol. For PQS2, both approaches resulted in the same LOD of 
200 amol. These values are in accordance to other SRM initiatives16,25.
Evaluation of PQS peptides upon transient expression of tagged proteins. To further demon-
strate the utility of these universal peptides for SRM analysis, we generated expression vectors that contain 
an N-terminal module which consists of the FLAG tag combined with the PQS1 peptide, and vectors with 
the N-terminal Myc-PQS2 peptide tag. Both PQS peptides were embedded in an optimal tryptic context as 
predicted by the cleavage prediction with decision trees (CP-DT) algorithm (LTLIFR-PQS1-FAYLYD and 
VAEAYR-PQS2-FLETEN)26. The well-studied interaction pair MyD88 and Mal from the TLR4 signaling path-
way27 was then cloned to obtain N-terminally tagged constructs with FLAG-PQS1 and Myc-PQS2 respectively. 
Upon transfection in HEK293T cells, the complex was purified using either anti-FLAG or anti-Myc antibody 
coupled to magnetic beads prior to on-bead digestion. Peak areas for each peptide behave as expected, corrob-
orating the use of the PQS peptides as SRM readout (Fig. 4A). Interestingly Myc-PQS2-Mal readouts showed 
significantly higher peak area ratios when normalized to their heavy labeled counterparts, which indicates that 
more Mal proteins were enriched when compared to MyD88 proteins. This is in accordance with literature stating 
Mal homodimerization can lead to the formation of potential binding platforms on the top and the side of the 
Mal dimer that bind MyD8828. All combinations showed a robust transition pattern (highest CV value detected: 
8.73%). To verify there was no non-specific binding of the peptides to the antibodies or beads we included a 
mock-interaction pair for each peptide. No signal could be observed when an unrelated prey (MARK3; NC1) or 
bait (HRAS; NC2) was used (Fig. 4A).
In addition to Mal-MyD88, we next tested the PQS peptides as readout for the LCP2-GRAP2 interaction 
involved in T-cell signaling29. Figure S-2 shows the reciprocal detection of the interaction using both FLAG-based 
immunoprecipitation (IP) and Myc-based IP of the associated baits. We also explored the clinically relevant 
binary interaction between p53 and its critical modulator MDM230. We monitored MDM2 retrieval by following 
the PQS2 peptide under basal conditions and under different treatment conditions that affect either the stability 
of the proteins (MG132) or the interaction between bait and prey (Nutlin331). Nutlin3 is a well-characterized 
small molecule that disrupts the autoregulator feedback loop between p53 and MDM2 by occupation of the p53 
binding site of MDM231–33. Indeed, we were able to show significant alterations in the monitored MDM2 levels in 
presence of Nutlin3 (independent t-test, p values: 0.0012 and 0.0006 in absence and presence of MG132 respec-
tively, Fig. 4B).
Integration of PQS peptides in endogenous proteins by genome engineering. We further 
explored the use of the PQS peptides by their introduction at the C-terminus of endogenous proteins. We 
used recombinant adeno-associated virus (rAAV) in combination with Clustered Regularly-Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 to generate a cell line that expresses an endogenous p53 protein containing a 
C-terminal combinatorial 3xFLAG-PQS1 tag (HCT116 TP53+/PQS1-FLAG). The tryptic context was also introduced 
to ensure optimal release upon tryptic digestion. We also generated a cell line containing the 3xHA-PQS2 tag 
fused to the C-terminus of MDM2 (HCT116 MDM2+/PQS2-HA) (Fig. 5A). Cell lines were validated by PCR anal-
ysis, DNA sequencing, Southern blot and Western blot (Supplementary Figures S-3 and S-4 respectively). Upon 
specific pull down of the bait protein (anti-FLAG for p53 and anti-HA for MDM2) a clear signal was observed in 
the enriched samples from engineered cell lines (p53 by PQS1, MDM2 by PQS2), while no signal was observed 
in control samples (Fig. 5B,C). Next, we assessed dynamic interaction profiles by increasing p53 protein levels 
Figure 3. Limit Of Detection (LOD) values for PQS1 (EAVSEILETSR) and PQS2 (GLGASPGIGAGR). 
 A dilution series of the peptide was spiked in a tryptic digest of HCT116 cells and transitions were monitored. 
(A) Calibration curve for each peptide depicting the average for 3 replicate runs with error bars of ± 1 SD.  
(B) LOD determination for PQS1 (top) and PQS2 (bottom) by the S/N method. For PQS1, the calibration curve 
(A) bends at 200 amol on column, but the signal still has a S/N > 3 at 100 amol (B). The peak area of PQS2 for 
the analysis of 100 amol is out of the calibration curve (A) and the transitions are not distinguishable anymore. 
The signal at 200 amol is still on the curve and has a S/N > 10 (B).
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through addition of Nutlin3. As expected, Nutlin3 treatment leads to increased levels of p53 and thus the PQS1 
peptide (Fig. 5B).
In a next step we monitored the interaction between p53 and MDM2. To this end, we created an additional cell 
line where the 3xFLAG-PQS1 tag sequence was introduced on endogenous p53 in the background of the engi-
neered MDM2 cell line, resulting in HCT116 TP53+/PQS1-FLAG MDM2+/PQS2-HA cells (Fig. 6A). This engineered cell 
line allows quantitative endogenous Co-IP analysis. Because of a high turnover rate, wild-type p53 and MDM2 
are typically expressed at low endogenous levels in most cultured cell lines including HCT116 cells. By using the 
PQS peptides as a proxy, we were able to detect the interaction in presence of MG132 when enriching for the 
complex by the HA-tag fused to MDM2 linked by the PQS2 peptide in the engineered HCT116 cells (Fig. 6B,C).
To explore direct detection and quantification of endogenous expressed proteins in a complex sample without 
the necessity to enrich or use tedious fractionation strategies, we used another engineered cell line wherein we intro-
duced the 3xFLAG-PQS1 combinatorial tag C-terminally in the IQGAP1 protein (HCT116 IQGAP1+/PQS1-FLAG; 
Fig. 7A). IQGAP1 is a key mediator of cytoskeletal rearrangements and is thought to play an important role in 
several cancer types by stimulating cell mobility and invasion34. Because of the involvement of IQGAP1 in cancer 
development, SRM experiments were described before to monitor expression levels in complex backgrounds with 
detection of 8.6 fmol using a SISCAPA approach35. For our assay, we developed a straightforward protocol which 
consists of minimal sample handling steps (see experimental procedures section). By spiking in heavy labeled 
peptide we were able to directly detect and quantify the PQS1 SRM peptide (Fig. 7B–D). Using the built-in peak 
detection feature in Skyline combined with manual curation of the signal, an average peak area ratio to heavy 
Figure 4. Use of PQS peptides to study binary interactions between tagged proteins upon expression 
in human cells. Peak Area Ratios to heavy (PAR) of summed transitions for PQS1 and PQS2 are shown for 
three experimental setups in HEK293T cells. In each sample, stable isotope labeled peptide were added to a 
final injected amount of 80 fmol. Each depicted sample was run in technical triplicate, error bars represent 
mean error values. A representative experiment is shown for 3 independent biological repeats. (A) Interaction 
between Mal and MyD88 as shown by PQS peptide quantification. Different combinations of FLAG-PQS1-
MyD88, Myc-PQS2-Mal and mock interactors (Myc-PQS2-MARK3 (NC1) and FLAG-PQS1-Ras (NC2)) were 
transfected. After immuno-precipitation using anti-FLAG or anti-Myc followed by on-bead tryptic digest, the 
levels of PQS1 and PQS2 were quantified by SRM. Independent t-test; all p values < 0.0001. (B) PQS peptide 
quantification for the interaction between p53 and MDM2. Different combinations of FLAG-PQS1-p53 and 
Myc-PQS2-MDM2 were expressed in human cells. The interaction was monitored in absence or presence of 
the proteasome inhibitor (MG132) or a small-molecule inhibitor of the p53 - MDM2 interaction (Nutlin3). 
A significance drop in signal by Nutlin3 addition could be observed both in absence and presence of MG132 
(Independent t-test, p values: 0.0012 and 0.0006 in absence and presence of MG132, respectively).
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(15 fmol) of 0.679 (CV value: 11.45%) was obtained, which translates to 10.18 fmol light peptide measured in 
5.14 μ g of sample. By including 7 transitions for detection and using eventually 4 transitions for analysis of both 
light and heavy peptide we are able to identify the correct peaks with high confidence (typical chromatograms are 
depicted in Fig. 7C,D).
Discussion
In this work we present small peptides flanked by optimal tryptic contexts that are characterized by optimal 
MS properties and thus allow SRM-based detection and quantification of proteins upon incorporation of the 
peptide sequence as a tag to the protein. The selected peptides are universally applicable being proteotypic for all 
Eukaryota and all strains of E. coli, thus covering a wide scope of model organisms used in life sciences. We were 
able to readily apply the defined peptides in overexpression experiments where Co-IP of selected protein pairs 
was studied. Moreover, we demonstrate the direct quantitative analysis of a human protein upon introduction of 
a PQS peptide by genome engineering using only one SRM assay in contrast to a classical setup in which a labor 
intensive SRM assay is developed for each protein, frequently with a low success rate. In addition, we show the 
use of these peptides for endogenous Co-IP experiments upon introduction in p53 and its interaction partner 
MDM2, which shows a high sensitivity of the PQS peptides. Variation in tryptic digest was minimized by provid-
ing these peptides in an optimal trypsin context that was derived by the aid of the CP-DT algorithm, alleviating 
the need for (complex) normalization approaches incorporated in the heavy labeled counterparts19,22.
Clearly, a possible disadvantage of our approach is the need to fuse the PQS peptide(s) to the protein(s) of 
interest. This can cause artifacts as the PQS tag may perturb protein folding, or have unexpected effects on tran-
scription or translation. We focused all genome engineering efforts on the C-terminus of the native protein, as we 
rationalized the risk of interference with regulatory elements is lower at this end of the protein36,37. Nevertheless, 
at this point it is hard to predict interference effects of fused sequences on protein expression, folding or interac-
tions and use of tagging by genome editing should be approached empirically. The incorporation of PQS peptides 
in an ‘Inntag’38 design process may minimize these artifacts.
Figure 5. Affinity purification followed by SRM analysis of PQS peptides introduced in endogenous 
proteins in human HCT116 cells. (A) Schematic representation of the two engineered HCT116 cell lines 
employed in this experiment. One of two alleles encodes for the tagged version of the protein. The PQS1-
3xFLAG combinatorial tag was introduced on the C-terminus of the endogenous p53 protein resulting in 
HCT116 TP53+/PQS1-FLAG MDM2+/+ cells, while the PQS2-3xHAtag was introduced on endogenous MDM2 
resulting in HCT116 TP53+/+ MDM2+/PQS2-HA cells. (B) Peak area ratio (PAR) measurement of 5 transitions of 
the PQS1 peptide after enrichment with anti-FLAG antibody. (C) PAR of 4 transitions of the PQS2 peptide after 
anti-HA mediated enrichment. The plots depict the peak area ratio of the light peptide to the heavy counterpart 
(PAR; final amount: 15 fmol injected).
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Classical Co-IP approaches typically rely on semi-quantitative Western analysis as a read-out39. The LUMIER 
approach where a luciferase-tagged prey is captured by an epitope-tagged bait is an alternative binary approach in 
which the luminescence read-out is accurately quantified40. However, bait quantification is completely lacking in 
this system. The PQS peptides presented here provide a simple and efficient way to quantify bait and prey both in 
lysates and enriched fractions. This information can be used to help elucidate the stoichiometry of the complex, 
and can provide information on the affinity of the associations41. Moreover, the actual protocol used to obtain the 
protein complexes can be optimized using the PQS peptides by monitoring losses in steps of the pull-down pro-
cess. The work from Hakhverdyan et al. clearly demonstrates a need for lysis optimization or even complemen-
tary lysis conditions to obtain a comprehensive view on a protein complex42. Use of the PQS peptides can now 
be extended to binary reference sets as described for the binary PPI approaches43. This will allow a side-by-side 
comparison between classical Co-IP pull down experiments and binary approaches such as yeast two-hybrid and 
MAPPIT44,45. While most of the published Co-IP data involves forced expression of bait and prey proteins, the 
revolution of genome engineering tools now allows the rapid engineering of epitope tags in endogenous proteins 
as demonstrated in this work37. Further optimization and streamlining of the SRM protocol for detection of the 
PQS peptides may allow the assessment of small molecule effects on protein expression or on PPIs as shown for 
the nutlin3 effect on the p53 - MDM2 interaction. Although true high-throughput screens may be too ambitious 
for this technology because of the sequential nature of the analysis, focused screens on lead(-optimized) com-
pounds are clearly within reach.
While we rely on the combinatorial use of well-defined affinity sequences to enrich for the protein(s) of interest 
which causes our tag sequences to grow considerable in length, it is theoretically possible to only depend on the 
PQS peptide for both enrichment and detection by generating (polyclonal) antibodies against the sequence46,47. 
This would enable inline enrichment of the peptides, boosting the sensitivity even further as described earlier 
in the SISCAPA approach14,48. To push accurate quantification even further, existing experimental setups such 
as QconCAT or universal cleavable reporter peptides can be incorporated when synthesizing heavy labeled ver-
sions of the peptides to provide more accurate quantification of peptides. Additionally, sensitivity can be further 
enhanced by tagging proteins with concatenated versions of the peptide. While the focus of this work lies on pro-
teomics and protein interactions we envision an extra applicability of PQS peptides for bioproduction purposes 
where these peptides could provide an elegant read-out system to monitor and optimize the production of biolog-
icals. In addition to the sensitive PQS peptides we were able to identify, this work also provides a robust workflow 
Figure 6. Detection of the p53-MDM2 interaction in HCT116 cells expressing tagged endogenous proteins. 
(A) Schematic representations of the engineered cell lines used for this experiment. The same cell lines were 
employed as in Fig. 5, with the addition of cell line expressing both MDM2 and p53 with a specific tag on the 
endogenous protein. (B,C) show peak area ratios (PAR) for the PQS1 and PQS2 peptide respectively after 
enrichment with anti-HA. The plots indicate the peak area ratio of the light peptide to the heavy counterpart 
(PAR, 5 fmol heavy peptide injected). 5 transitions were followed for every peptide in each run.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:27220 | DOI: 10.1038/srep27220
to identify sensitive and proteotypic peptides from any given host organism. Theoretically, this workflow could be 
expanded to search optimal PQS peptides in a wide collection of organisms, which may lead to the identification 
of more and perhaps better PQS peptides useful for detection and quantification of proteins expressed at very low 
levels in complex samples.
Experimental procedures
In silico selection of candidate SRM peptides. For initial selection of the PQS peptides, we first analyzed 
the Agilent complex proteomics standard as a source for P. furiosus proteins using a classical shotgun approach. 
The exact experimental details can be found in the supplementary information.
Identification data from the P. furiosus proteome was retrieved from ms_lims49 and used to compute metrics 
for the selection of optimal SRM peptides. For every identified peptide, the average matched intensity was com-
puted in each of the three discovery experiments as follows. First, absolute intensities of all matched singly and 
Figure 7. Detection and quantification of PQS1 for endogenous IQGAP1 in engineered HCT116 
IQGAP1+/PQS1-FLAG cells. (A) Peak area ratio (PAR) for individual transitions of the PQS1 peptide compared to 
wild-type HCT116 cells. Heavy peptide was added to the sample to a final amount of 15 fmol heavy peptide on 
column. (B) PAR for the PQS1 peptide in HCT116 IQGAP1+/PQS1-FLAG cells and background signal in a wild-
type HCT116 population. Each sample depicts three technical repeats with a final amount of 15 fmol heavy 
PQS1 peptide. Independent t-test, p value: 0.0021. (C) Typical chromatograms of monitored transitions for the 
light (top) and heavy (bottom) PQS1 peptide. (D) Typical chromatogram of parental (wild type) HCT116 cells. 
Three transitions were omitted due to background interference as described in the experimental procedure 
section.
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doubly charged b and y fragment ions were summed for each peptide-spectrum match (PSM). Subsequently, 
these matched intensity values were averaged across the number of PSMs for each identified peptide sequence to 
yield an average matched peptide intensity. Only peptides that matched uniquely to a single protein entry were 
considered. Moreover, peptides that matched to a protein that was identified with at least three peptides were 
retained for downstream evaluation. For each protein, the location and scale of the average matched peptide 
intensity distributions were estimated through the median and mean absolute deviation (MAD), respectively. 
These values were calculated from the list of average matched peptide intensities for each protein by robust Huber 
statistics as implemented in the ‘huber’ function of the R ‘MASS’ package. This function applies iterative winsori-
zation to reduce the effect of outliers on the distribution of values50. The k parameter that determines the outlier 
range was set to 1.2. The Huber median and MAD values were then used to compute a differential score for each 
peptide using the formula =
−
differential score
I m
s
pep i j j
j
( , ) ; where Ipep(i, j) is the average matched peptide intensity for 
peptide i of protein j, mj is the huber median of the average matched peptide intensities for protein j, and sj is the 
huber MAD of the average matched peptide intensities for protein j. An additional calculation was done for the 
fragmentation efficiency, indicated by the fragment ion coverage. For each identified peptide, the number of 
annotated ions for every spectrum were summed and averaged over the three discovery experiments.
Uniqueness of the final selection of P. furiosus peptides was then verified by mapping the peptide sequences 
back, irrespective of any cleavage rules, to the corresponding UniProt protein databases of all Eukaryota (UniProt 
release-2015_09; 181,063 protein sequences), and all Escherichia coli strains (UniProt, release 2015_09; 23,008 
protein sequences) with DBToolkit51.
Evaluation of predicted PQS peptides. The 15 best in silico predicted PQS peptides were synthesized 
in-house using standard solid-phase Fmoc chemistry on a Syrol peptide synthesizer (Biotage) and purified by 
RP-HPLC. For the initial evaluation of in silico predicted peptides, 100 fmol of each peptide was analyzed on the 
TSQ Vantage LC-SRM system operated as described in the supplementary experimental procedures section. 
Here, the collision energy was experimentally optimized through Skyline. From this analysis, the 8 most efficient 
transitions of these 15 peptides were derived. To challenge the peptides in a complex sample, a dilution series (to 
final injection amounts of 25, 50, 100, 150, 250 and 400 fmol) of a mix containing the 15 peptides (Table 1) was 
spiked into a tryptic digest of HCT116 cells (ATCC) (1 μ g on column) and analyzed with timed SRM. For the final 
ranking of the best peptides, two criteria were taken into account: 1) intensity of the total peak area of all transi-
tions and 2) an optimal equal distribution of the peak areas for each transition.
All Skyline files used for obtaining data presented in this work, both targeted and P. furiosus discovery 
experiments were uploaded using Panorama52 and are publicly available at https://panoramaweb.org/labkey/
PQSpeptides.
Limit of detection experiment. The two most intense PQS peptides, designated PQS1 and PQS2, were 
spiked in a tryptic digest of HCT116 cells (0.5 μ g injected) in separate dilution series (final injected amounts: 0.1, 
0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 fmol) for each peptide. To each sample, the appropriate heavy labeled counterpart 
was added to a final injection amount of 5 fmol as reference for quantification, instrument stability and peak 
identification facilitation. The final LOD values correspond to the lowest detectable amount of light peptide (i.e. 
S/N > 3) in the sample series for each peptide. Standard deviations were calculated based on the extracted mean 
standard error values from Skyline.
In silico prediction of the optimal tryptic context. The two selected PQS peptides were in silico evalu-
ated for their tryptic propensity when inserted into the human proteome. We therefore first determined all tryptic 
peptides from the human proteome with the aid of DBToolkit51. Next, each human tryptic peptide was added 
both before and after the PQS peptide of interest. The resulting merged peptide library was subsequently submit-
ted to the CP-DT algorithm26. CP-DT is based on a decision tree ensemble learned on publicly available peptide 
identifications and calculates the probability of cleavage by trypsin of the tryptic position within each merged 
peptide. For each PQS peptide, the merged peptides were then ranked according to the probability of cleavage by 
trypsin. The top ranked merged peptides, the peptides with the highest probability of cleavage by trypsin, were 
used for further analysis.
cDNA plasmid generation. cDNA coding for proteins of interest was obtained from the human ORFeome 
collection (v8.1, http://horfdb.dfci.harvard.edu/)53. Constructs were inserted into pMet7-FLAG-PQS1 or 
pMet7-Myc-PQS2 backbone plasmids by Gateway cloning, fusing the affinity sequence and corresponding PQS 
peptides flanked by their optimal tryptic context to the N-terminus of the protein-coding cDNA. All final con-
structs were verified by restriction digest and Sanger sequencing. Detailed outlines regarding transfection, cell 
lysis and affinity purification can be found in the supplementary experimental procedures.
Endogenous protein tagging based on recombinant adeno-associated virus and CRISPR/
Cas9. Recombinant adeno-associated virus (rAAV)-based genome editing was performed on HCT116 cells 
cultured in McCoy’s 5A medium in presence of 10% fetal bovine serum (Gibco). Virus production was per-
formed in AAV-293 cells (Agilent) by Polyethylenimine (PEI) co-transfection of a modified pAAV-MCS plas-
mid (Agilent), hereafter referred to as targeting vector and the pDG vector (Plasmidfactory). For generation of 
HCT116 TP53+/PQS1-FLAG and HCT116 IQGAP1+/PQS1-FLAG engineered cell lines, the final targeting vector con-
sisted of two homology regions of each approximately 1,000 bp length spanning the C-terminus of the target gene 
embedding the PQS1 peptide flanked by an optimal tryptic context and a 3xFLAG-tag. After the stop codon, 
a floxed neomycin selection cassette (Genscript, custom DNA synthesis) was inserted for selection purposes. 
Homology regions were picked up by genomic PCR on HCT116 DNA. Separate inserts were simultaneously 
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ligated using In-Fusion cloning kits (Clontech). All primer sequences and DNA constructed by DNA synthesis 
can be found in Supplementary Table S-1. For generation of HCT116 MDM2+/PQS2-HA cells, the PQS2 peptide 
was inserted and the 3xFLAG sequence was exchanged for a 3xHA-tag. 24 h after transfection, the medium was 
refreshed and after 48 h of additional incubation viral stocks were prepared using the AAV purification ViraKit 
(Virapur) according to the protocol provided by the manufacturer. Engineering of p53 was performed by a com-
bination of rAAV and CRISPR/Cas9 whereby rAAV infection was done one day after Cas9 transfection using 
FugeneHD (Promega). CRISPR guide RNAs (gRNAs) (Supplementary Table S-2) were used based on in silico 
activity prediction using the online Zhang Lab CRISPR design tool (http://crispr.mit.edu/) and constructed in 
Streptococcus pyogenes Cas9 in the pSpCas9(BB)-2A-Puro vector (PX459, Addgene) according to the protocol 
published by Ran et al.54. Activity of the gRNAs was assessed experimentally by transfecting the different con-
structs and cleavage of the target region was assessed using the Surveyor® mutation detection kit (Integrated 
DNA Technologies) (Supplementary Figure S-5). Only the most potent gRNA was further used for the generation 
of knock-in cell lines. The HCT116 TP53+/PQS1-FLAG MDM2+/PQS2-HA cells were generated by additional genome 
engineering using the rAAV-CRISPR/Cas9 combination for TP53 on HCT116 MDM2+/PQS2-HA cells. The detailed 
genome engineering workflow and clonal screening can be found in the supplementary experimental procedures.
Sample preparation from engineered cell lines. For direct detection of the SRM peptides in cell lysates 
without prior enrichment, subconfluent 145 cm2 petri dish engineered clonal HCT116 populations were lysed in 
100 μ l 20 mM ammonium acetate by freeze-thawing after detaching the cells with cell dissociation buffer (Gibco). 
Digestion occurred overnight by addition of trypsin equal to 1% of the total protein concentration of the sample 
as determined by Bradford assay. Prior to transferring the sample to a MS vial, Trifluoroacetic Acid (TFA) was 
added to a final concentration of 0.1% and the sample was centrifuged at 16,000 g for 10 min to remove any debris.
Protocols regarding endogenous affinity purification experiments are described in supplementary experimen-
tal procedures.
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